Daniel O’Day

Roche to fully acquire Ignyta for US$ 1.7 billion in an all-cash transaction

Roche to acquire Ignyta for US$ 27.00 per share Ignyta’s investigational medicine entrectinib, a selective CNS-active tyrosine-kinase inhibitor being developed…

6 years ago

Roche to acquire up to 56.3% interest in Foundation Medicine, Inc. on a fully diluted basis through a tender and acquisition of newly issued shares

BASEL, 12-1-2015 — /EuropaWire/ — Collaboration leverages both companies’ strengths to advance the progress of personalized treatments for patients with…

9 years ago

Roche to invest CHF 800 million to increase production capabilities for its biologic medicines

Investment to help meet rising demand for licensed biologics and expected pipeline growth Basel, Switzerland, 16-10-2013 — /EuropaWire/ — Roche (SIX: RO,…

11 years ago